Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients

The purpose of this study is to evaluate the efficacy and safety of Nintedanib with EGFR-TKI in participants with advanced EGFR-TKI-resistant non-small cell lung cancer

Trial Details

NCT ID
NCT06071013
Phase
PHASE1 / PHASE2
Sponsor
China Medical University Hospital
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Nintedanib, gefitinib, erlotinib, afatinib, osimertinib
Locations (sample)
  • Taichung, Taiwan|24.1469,120.6839

Key Eligibility Criteria

  • Participants between 20 to 70 years old, are pathologically confirmed advanced (stage III and IV) non-small cell lung cancer.
  • Positive EGFR mutations are diagenesis.
  • Participants with histologically/cytologically confirmed locally advanced or metastatic adenocarcinoma subtype NSCLC after the failure of first-lin…
  • Participants must have adequate hepatic, renal, and bone marrow function

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →